Chugai Pharmaceutical Publishes Transcript of FY2026 Q3 Financial Results Conference
Bitget2026/10/28 11:52- Chugai Pharmaceutical’s October 27, 2026, FY2026 third-quarter results conference featured CEO Osamu Okuda and CFO Iwaaki Taniguchi.
- Nine-month revenue reached JPY 1.07 trillion; core operating profit totaled JPY 536.1 billion.
- Management expects to exceed its full-year forecast, with Actemra sales projected to beat expectations by more than JPY 10 billion.
- ERP-related shipment front-loading boosted domestic sales by the low JPY 30 billion range; the one-time benefit will reverse in the fourth quarter.
- Hemlibra’s autoinjector launch is targeted for Japan and global markets in 2027, with no material increase in the cost ratio expected.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
